New combo therapy shows promise for tough kidney cancer
NCT ID NCT02535533
First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs, axitinib and seleniomethionine, in 45 adults with advanced kidney cancer that had spread. The goal was to find a safe dose and see if the combination could help control the cancer. The trial was completed and focused on side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.